Sökning: WFRF:(Pak Hui Nam)
> (2022) >
Efficacy and safety...
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function : Post hoc analyses of the EURIDIS-ADONIS trials
-
Thind, Munveer (författare)
-
- Zareba, Wojciech (författare)
- University of Rochester
-
- Atar, Dan (författare)
- Oslo university hospital,University of Oslo
-
visa fler...
-
- Crijns, Harry J.G.M. (författare)
- Maastricht University
-
- Zhu, Jun (författare)
- Fu Wai Hospital
-
- Pak, Hui Nam (författare)
- Yonsei University
-
- Reiffel, James (författare)
- Columbia University
-
- Ludwigs, Ulf (författare)
- Sanofi AB
-
- Wieloch, Mattias (författare)
- Lund University,Lunds universitet,Klinisk koagulationsmedicin, Malmö,Forskargrupper vid Lunds universitet,Clinical Coagulation, Malmö,Lund University Research Groups,Sanofi S.A., France
-
Stewart, John (författare)
-
- Kowey, Peter (författare)
- Lankenau Institute for Medical Research
-
visa färre...
-
(creator_code:org_t)
- 2022-01-12
- 2022
- Engelska 9 s.
-
Ingår i: Clinical Cardiology. - : Wiley. - 0160-9289 .- 1932-8737. ; 45:1, s. 101-109
- Relaterad länk:
-
http://dx.doi.org/10... (free)
-
visa fler...
-
https://onlinelibrar...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: The use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is complex because impaired renal clearance can cause increased drug levels, and risk of intolerance or adverse events. Due to the propensity for CKD to occur alongside atrial fibrillation/atrial flutter (AF/AFL), it is essential that AAD safety and efficacy are assessed for patients with CKD. Hypothesis: Dronedarone, an approved AAD, may present a suitable therapeutic option for patients with AF/AFL and concomitant CKD. Methods: EURIDIS-ADONIS (EURIDIS, NCT00259428; ADONIS, NCT00259376) were identically designed, multicenter, double-blind, parallel-group trials investigating AF/AFL control with dronedarone 400 mg twice daily versus placebo (randomized 2:1). In this post hoc analysis, the primary endpoint was time to first AF/AFL. Patients were stratified according to renal function using the CKD-Epidemiology Collaboration equation and divided into estimated glomerular filtration rate (eGFR) subgroups of 30–44, 45–59, 60–89, and ≥90 ml/min. Time-to-events between treatment groups were compared using log-rank testing and Cox regression. Results: At baseline, most (86%) patients demonstrated a mild or mild-to-moderate eGFR decrease. Median time to first AF/AFL recurrence was significantly longer with dronedarone versus placebo for all eGFR subgroups except the 30 to 44 ml/min group, where the trend was similar but statistical power may have been limited by the small population. eGFR stratification had no significant effect on serious adverse events, deaths, or treatment discontinuations. Conclusions: This analysis suggests that dronedarone could be an effective therapeutic option for AF with an acceptable safety profile in patients with impaired renal function.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Thind, Munveer
-
Zareba, Wojciech
-
Atar, Dan
-
Crijns, Harry J. ...
-
Zhu, Jun
-
Pak, Hui Nam
-
visa fler...
-
Reiffel, James
-
Ludwigs, Ulf
-
Wieloch, Mattias
-
Stewart, John
-
Kowey, Peter
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Clinical Cardiol ...
- Av lärosätet
-
Lunds universitet